G. Shapiro

Oncology · New England Journal of Medicine · 2006–2020

A researcher in the Science corpus: 12 papers; trusts 3 researchers and is trusted by 8 researchers here, as inferred from the citation graph.

Subfields

Whom G. Shapiro trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. C. Sherr
  2. J. Harbour
  3. Marcos Malumbres
  4. J. M. Roberts

Who trusts G. Shapiro overall

  1. E. Musgrove
  2. S. Lapenna
  3. Marcos Malumbres
  4. M. Li‐Weber
  5. M. Butler

Papers from G. Shapiro's perspective

Ordered by how strongly the researchers G. Shapiro trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice (Nature Genetics)
  2. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy (Nature)
  3. Cdk2 Knockout Mice Are Viable (Current Biology)
  4. Specific protection against breast cancers by cyclin D1 ablation (Nature)
  5. The Rb/E2F pathway: expanding roles and emerging paradigms. (Genes & Development)
  6. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase (Nature)
  7. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. (Molecular Cancer Therapeutics)
  8. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. (Blood)
  9. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. (The Lancet Oncology)
  10. Whole–genome characterization of chemoresistant ovarian cancer (Nature)

Their papers